Focus and Scope

The "Journal of Modern Oncology" is an open access, peer-reviewed online journal dedicated to providing the very latest information both in clinical and translational research fields related to a wide range of topics in oncology. 

The journal publishes editorial conference updates, original research, reviews, clinical case reports, commentaries, clinical and laboratory observations by Russian and international authors, pertinent to readers in CIS countries and around the world.

Special area focus/ journal sections:

  •  Diagnosis of cancer
  •  Tumors of the respiratory system
  •  Ovarian and cervical tumors
  •  Tumors of the digestive tract
  •  Radiation therapy, chemotherapy, targeted therapy of tumors
  •  Quality of life of patients

 

Sections

CLINICAL ONCOLOGY

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Guidelines

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Conference Proceedings

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Review

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Original Article

Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Peer Review Process

An double anonymous ("blind") peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of “Journal of Modern Oncology”. This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer.

  1. Members of the editorial board and leading Russian and international experts in corresponding areas of life sciences, invited as independent readers, perform peer reviews. Editor-in-chief, deputy editor-in-chief or science editor choose readers for peer review. We aim to limit the review process to 2-4 weeks, though in some cases the schedule may be adjusted at the reviewer’s request.
  2. Reviewer has an option to abnegate the assessment should any conflict of interests arise that may affect perception or interpretation of the manuscript. Upon the scrutiny, the reviewer is expected to present the editorial board with one of the following recommendations: 
    - to accept the paper in its present state; 
    - to invited the author to revise their manuscript to address specific concerns before final decision is reached; 
    - that final decision be reached following further reviewing by another specialist; 
    - to reject the manuscript outright.
  3. If the reviewer has recommended any refinements, the editorial staff would suggest the author either to implement the corrections, or to dispute them reasonably. Authors are kindly required to limit their revision to 2 months and resubmit the adapted manuscript within this period for final evaluation.
  4. We politely request that the editor to be notified verbally or in writing should the author decide to refuse from publishing the manuscript. In case the author fails to do so within 3 months since receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the author accordingly.
  5. If author and reviewers meet insoluble contradictions regarding revision of the manuscript, the editor-in-chief resolves the conflict by his own authority.
  6. The editorial board reaches final decision to reject a manuscript on the hearing according to reviewers’ recommendations, and duly notifies the authors of their decision via e-mail. The board does not accept previously rejected manuscripts for re-evaluation.
  7. Upon the decision to accept the manuscript for publishing, the editorial staff notifies the authors of the scheduled date of publication.
  8. Kindly note that positive review does not guarantee the acceptance, as final decision in all cases lies with the editorial board. By his authority, editor-in-chief rules final solution of every conflict.
  9. Original reviews of submitted manuscripts remain deposited for 3 years.

 

Publication Frequency

4 issues per year

 

Open Access Policy

  • The publication in the Journal for author is free of charge whereas the author passes the rights for commercial use to the Publisher.
  • This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
  • This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
  • The Publisher retains the rights for commercial reprints. Any requests for reprints shall be e-mailed.

 

Editorial Board

EDITOR-IN-CHIEF

Irina V. Poddubnaya – M.D., Ph.D., Professor, Academician of the Russian Academy of Sciences, Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Scopus Author ID: 6603818617; ORCID ID: 0000-0002-0995-1801

 

 

EDITORIAL BOARD

Ivan S. Stilidi – M.D., Ph.D., Professor, Corresponding Member of the Russian Academy of Sciences, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia; PubMed, Scopus Author ID: 6602949492

Andrei V. Vazhenin – M.D., Ph.D., Professor, Academician of the Russian Academy of Sciences, Chelyabinsk Regional Center of Oncology and Nuclear Medicine, South Ural State Medical University, Chelyabinsk, Russia; PubMed, Scopus Author ID: 7003627756

Vera A. Gorbunova – M.D., Ph.D., Professor, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia, Scopus Author ID: 57198298888 ; ORCID ID: 0000-0003-0703-2550PubMed

Victoria V. Dvornichenko – M.D., Ph.D., Professor, Irkutsk Medical Academy of Postgraduate Education – branch of Russian Medical Academy of Continuous Professional Education, Regional Cancer Center, Irkutsk, Russia; PubMed; Scopus Author ID: 6507106163 ; ORCID ID: 0000-0002-1777-5449

Kirill I. Zhordaniya – M.D., Ph.D., Professor, N.N. Blokhin National Medical Research Center of Oncology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia, Scopus Author ID: 6506797842; ORCID ID: 0000-0003-1380-3710

Zaira G. Kadagidze – M.D., Ph.D., Professor, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia, Scopus Author ID: 7006314985 ; ORCID ID: 0000-0002-0058-0987

Alexander F. Lazarev – M.D., Ph.D., Professor, Altai State Medical University, Barnaul, Russia, Scopus Author ID: 36166916600 ; ORCID ID: 0000-0003-1080-5294

Vladimir M. Moiseenko – M.D., Ph.D., Professor, Saint Petersburg Сlinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), Saint Petersburg, Russia, Scopus Author ID: 7102755712

Vladimir G. Polyakov – M.D., Ph.D., Professor, Academician of the Russian Academy of Sciences, Russian Medical Academy of Continuous Professional Education, Moscow, Russia, Scopus Author ID: 11240515400 ; ORCID ID: 0000-0002-8096-0874

Rustem Sh. Khasanov – M.D., Ph.D., Professor, Corresponding Member of the Russian Academy of Sciences, Kazan State Medical Academy, Kazan, Russia, Scopus Author ID: 15048020700 ; ORCID ID: 0000-0003-4107-8608

 

EDITORIAL COUNCIL

Mamed D. Aliev – M.D., Ph.D., Professor, Academician of the Russian Academy of Sciences, National Medical Research Radiological Center, Moscow, Russia, Scopus Author ID: 7102826625 ; ORCID ID: 0000-0003-2706-4138

Avgust M. Garin – M.D., Ph.D., Professor, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia, Scopus Author ID: 7006116200

Mikhail I. Davydov – M.D., Ph.D., Professor, Academician of the Russian Academy of Sciences, Russian Association of Oncologists, Moscow, Russia, Scopus Author ID: 7003627756; ORCID ID: 0000-0001-6257-3873

Andrey D. Kaprin – M.D., Ph.D., Professor, Academician of the Russian Academy of Sciences, National Medical Research Radiological Center, Moscow, RussiaScopus Author ID: 6602709853; ORCID ID: 0000-0001-8784-8415

Nikolay E. Kushlinskii – M.D., Ph.D., Professor, Corresponding Member of the Russian Academy of Sciences, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia, Scopus Author ID: 7005430266 ORCID ID: 0000-0002-3898-4127

Sergey A. Tyulyandin – M.D., Ph.D., Professor, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia, Scopus Author ID:  6508175205

Cornelis Van de Velde – M.D., Ph.D., Professor, Leiden University Medical Centre, Leiden, The Netherlands, Scopus Author ID: 57202638098,  ORCID ID: 0000-0003-0104-1800

Andrea Gallamini – M.D., Professor, Antoine-Lacassagne Cancer Center, Nice, France, Scopus Author ID: 7003909433 

Volker Diehl – M.D., Professor, German Hodgkin Study Group, University of Cologne, Cologne, Germany, Scopus Author ID: 55225457000 ORCID ID: 0000-0002-7334-6104

Martin Dreyling – M.D., Professor, Department of Internal Medicine, University of Munich, Munich, Germany, Scopus Author ID: 6603699070

Franco Cavalli – M.D., Professor, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, Scopus Author ID: 7103021766

Antonio Llombart – M.D., Professor, Department of Oncology, Hospital Arnau de Vilanova, Valencia, Spain , Scopus Author ID: 6603669381

Andreas Engert – M.D., Professor, German Hodgkin Study Group, University Hospital of Cologne, Cologne, Germany, Scopus Author ID: 7102240400 

 

EXECUTIVE SECRETARIES

Ludmila E. Komarova – Dr. Sci. (Biol.), Professor, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia, Scopus Author ID: 7102405927


Sergey O. Podvyaznikov – M.D., Ph.D., Professor, Russian Medical Academy of Continuous Professional Education, Moscow, Russia

 

Indexing

Articles in “Journal of Modern Oncology” are indexed by several systems:
 
Science Citation of Elibrary.ru - Regional Index of scientific journals in Russian Federation.
 
 
Ulrich’s Periodicals Directory – is the standard library directory and database providing information about popular and academic magazines, scientific journals, newspapers and other serial publications.    
 
WorldCat is a union catalog that itemizes the collections of 72,000 libraries in 170 countries and territories that participate in the Online Computer Library Center (OCLC) global cooperative. 
 
CyberLeninka is online sci-hub library based on the open science paradigm
 
 
VINITI Database RAS is a database provided by the All-Russian Institute for Scientific and Technical Information (VINITI). The database is devoted to scientific publications. It is described as a large abstracting database. In general, it is indexed for the natural sciences, exact sciences, and technical sciences. Included in this database is AJ (Abstract Journal), indexed from 1981 to the present day.

 

Publishing Ethics and Malpractice Statement

The "Journal of Modern Oncology" use native plagiarism detection software Antiplagiat to screen the submissions. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.

 

  1. Introduction

1.1. The publication in a peer reviewed journal serves many purposes outside of simple communication. It is a building block in the development of a coherent and respected network of knowledge. For all these reasons and especially for biomedical journals (whereas the ethical issues is extremely sensitive subject) it is important to lay down standards of expected ethical behavior by all parties involved in the act of publishing: the author, the journal editor, the peer reviewer, and the publisher (in some cases the society/ other possible proprietor of the journal).

1.2. Publisher has a supporting, investing and nurturing role in the scholarly communication process but is also ultimately responsible for ensuring that best practice is followed in its publications.

1.3. Publisher takes its duties of guardianship over the scholarly record extremely seriously. Our  responsibilities is to ensure the journal’s coherence to the most current ethical guidelines and policies at every stage from designing and conducting research or clinical study to properly wring and submitting a manuscript as established by the relevant international bodies or policies  to include but not limited to the following:

 

  • WMA Declaration of Helsinki (ethical principles for medical research involving human and animal subjects)
  • ICMJE (International Committee of Medical Journal Editors)
  • COPE (Committee on Publication Ethics)
  • CONSORT (randomized control studies)
  • STROBE (observation studies)
  • PRISMA (meta-analyses, systematic reviews and other evaluation studies)

 

1.4. Over 20 potential Malpractices are examined below that could be relevant not only to an author (see clauses 4.1. - 4.10.) but also to an editor and a reviewer (see clauses 2.2.-2.6; 3.1.-3.6.) as result of their possible dereliction of professional duty. 

 

 

  1. Duties of Editors

2.1. Publication decision – The Editor of the “Journal of Modern Oncology”  is solely and independently responsible for deciding which of the articles submitted to the journal should be published, often working on conjunction with the relevant society (for society-owned or sponsored journals). The validation of the work in question and its importance to researchers and readers must always underwrite such decisions. The Editor may be guided by the policies of the “Journal of Modern Oncology” journal’s editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers (or society officers) in making this decision.

2.2. Fair play – An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.

2.2.3. Libel and Defamation– An editor should be alert to language in both submitted manuscripts and also in peer review reports or correspondence which could give rise to legal action for defamation or negligent misstatement. Such language, which can be directed at corporate entities and associations as well as individuals, should not appear within published articles and should be removed from any peer review report or correspondence that is passed on to the author. If in doubt, editors should seek advice from the Publisher. 

2.3. Confidentiality – The editor and any editorial staff of “Journal of Modern Oncology”  must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.

2.4. Disclosure and Conflicts of interest

2.4.1. Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

2.4.2. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from considering manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) institutions connected to the papers.

2.5. Vigilance over published record – An editor presented with convincing evidence that the substance or conclusions of a published paper are erroneous should coordinate with the publisher (and/or society) to promote the prompt publication of a correction, retraction, expression of concern, or other note, as may be relevant.

2.6.Involvement and cooperation in investigations – An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Such measures will generally include contacting the author of the manuscript or paper and giving due consideration of the respective complaint or claims made, but may also include further communications to the relevant institutions and research bodies.

 

  1. Duties of Reviewers

3.1. Contribution to Editorial Decisions – Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. Peer review is an essential component of formal scholarly communication, and lies at the heart of the scientific method. Publisher shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.

3.2. Promptness – Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor of “Journal of Modern Oncology”  and excuse himself from the review process.

3.3. Confidentiality – Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorised by the editor.

3.4. Standard and objectivity – Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.

3.5. Acknowledgement of Sources – Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor’s attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.

3.6. Disclosure and Conflict of Interest

3.6.1. Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

3.6.2. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

 

  1. Duties of Authors

4.1. Reporting standards

4.1.1. Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.

4.1.2. Review and professional publication articles should also be accurate and objective, and editorial 'opinion’ works should be clearly identified as such.

4.2. Data Access and Retention – Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

4.3. Originality andPlagiarism

4.3.1. The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others, this has been appropriately cited or quoted.

4.3.2. Plagiarism takes many forms, from ‘passing off’ another’s paper as the author’s own paper, to copying or paraphrasing substantial parts of another’s paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behaviour and is unacceptable.

4.4. Multiple, Redundant or Concurrent Publication

4.4.1. An author should not in general publish manuscripts describing essentially the same research in more than one journal of primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and is unacceptable.

4.4.2. In general, an author should not submit for consideration in another journal a previously published paper.

4.4.3. Publication of some kinds of articles (eg, clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication. 

4.5. Acknowledgement of Sources – Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

4.6. Authorship of the Paper

4.6.1. Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.

4.6.2. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

4.7. Hazards and Human or Animal Subjects

4.7.1. If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.

4.7.2. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

4.7.3. In case of clinical trials authors are required to provide registration of clinical trials in a public trials registry at or before the time of first patient enrollment. 

We accept publicly accessible registration in any registry that is a primary register of the WHO International Clinical Trials Registry Platform (ICTRP) or in ClinicalTrials.gov, which is a data provider to the WHO ICTRP.

 

4.8. Disclosure and Conflicts of Interest

4.8.1. All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.

4.8.2. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest possible stage.

4.9. Fundamental errors in published works – When an author discovers a significant error or inaccuracy in a published work, it is the author’s obligation to promptly notify the editor of “Journal of Modern Oncology” journal and cooperate with Publisher to retract or correct the paper, If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper.

4.10. Libel and use of inclusive language-Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

 

 

  1. Duties of the Publisher (and if relevant, Society)

5.1. Publisher should adopt policies and procedures that support editors, reviewers and authors of “Journal of Modern Oncology” in performing their ethical duties under these ethics guidelines. The publisher should ensure that the potential for advertising or reprint revenue has no impact or influence on editorial decisions.

5.2. The publisher should support “Journal of Modern Oncology”  journal editors in the review of complaints raised concerning ethical issues and help communications with other journals and/or publishers where this is useful to editors.

5.3. Publisher should develop codes of practice and inculcate industry standards for best practice on ethical matters, errors and retractions.

5.4. Publisher should provide specialized legal review and counsel if necessary.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies